Effect of neoadjuvant chemotherapy in combined with laparoscopy on the molecular markers and immune function in patients with locally advanced cervical cancer

摘要

Objective: To explore the efficacy of paclitaxel plus cisplatin (TP) neoadjuvant chemotherapyin combined with laparoscopy in the treatment of locally advanced cervical cancer and theireffect on the molecular markers and immune function. Methods: A total of 92 patients withlocally advanced cervical cancer were included in the study and divided into the control group(n=46) and the treatment group (n=46) according to the admission number. The patients inthe control group were given 5- fluorouracil plus cisplatin (PF), neoadjuvant chemotherapy incombined with laparoscopic radical hysterectomy. The patients in the treatment group weregiven TP neoadjuvant chemotherapy in combined with laparoscopic radical hysterectomy.The clinical efficacy in the two groups was compared. The levels of molecular markers andthe change of immune function in the two groups were detected and compared. The adversereactions in the two groups were observed and compared. Results: After chemotherapy, inthe treatment group, CR was 39.13%, PR was 41.30%, NC was 13.04%, PD was 6.52%, andthe total effective rate was 80.43%, while those in the control group were 21.74%, 26.09%,30.43%, 21.74%, and 47.83%, respectively. The total effective rate in the treatment groupwas significantly higher than that in the control group. The comparison of the occurrencerate of adverse reactions between the two groups was not statistically significant. CEA,SCC-Ag, CYFRA21-1, and CA125 levels 2 weeks after operation in the two groups weresignificantly reduced when compared with before treatment, and those in the treatment groupwere significantly lower than those in the control group. MMP-2, TIMP-2, VEGF-C, andVEGF-D levels 2 weeks after operation in the two groups were significantly reduced whencompared with before treatment, and those in the treatment group were significantly lowerthan those in the control group. CD3+, CD4+, and CD8+ 2 weeks after operation in the twogroups were significantly reduced when compared with before treatment, while CD4+/CD8+was significantly elevated, but the comparison between the two groups was not statisticallysignificant. Conclusions: Given TP neoadjuvant chemotherapy in combined with laparoscopyin patients with locally advanced cervical cancer can obviously enhance the patient's clinicalefficacy, reduce the molecular markers in the body, effectively improve the patient's immunefunctionwith less adverse reactions and accurate efficacy; therefore, they are safe and reliable.